Differential effects of enzyme induction on antipyrine metabolite formation. 1982

M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer

1 The influence of enzyme induction with antipyrine and pentobarbitone was studied on the rates of formation of the major metabolites of antipyrine: 4-hydroxyantipyrine, norantipyrine and 3-hydroxymethyl-antipyrine + 3-carboxy-antipyrine. The inducing drugs were given to panels of healthy volunteers for 8 days and prior to and after this period antipyrine total elimination clearance was determined in plasma, whereas the partial clearances for production of the individual metabolites were assessed on the basis of urinary excretion data. 2 Antipyrine total clearance had significantly increased by 16% following treatment with antipyrine, which could almost entirely be attributed to a selective increase in the rate of production of norantipyrine. 3 With pentobarbitone total clearance of antipyrine had increased by 60%, which was associated with a significant increase in the clearance of production of all three metabolites. However, the increase in norantipyrine formation was significantly higher than the increase in 4-hydroxyantipyrine and 3-hydroxymethyl-antipyrine formation. 4 The most likely explanation for these differences in the degree of induction of the different metabolic routes of antipyrine, is that different enzymes are involved in the different routes. Apparently the enzyme involved in norantipyrine formation is most sensitive to induction by antipyrine and pentobarbitone. By measuring rates of antipyrine metabolite formation it may be possible to study the degree of selectivity of enzyme inducers on oxidative drug metabolism.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010424 Pentobarbital A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) Mebubarbital,Mebumal,Diabutal,Etaminal,Ethaminal,Nembutal,Pentobarbital Sodium,Pentobarbital, Monosodium Salt,Pentobarbitone,Sagatal,Monosodium Salt Pentobarbital
D004790 Enzyme Induction An increase in the rate of synthesis of an enzyme due to the presence of an inducer which acts to derepress the gene responsible for enzyme synthesis. Induction, Enzyme
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
January 1984, European journal of clinical pharmacology,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
December 1986, Xenobiotica; the fate of foreign compounds in biological systems,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
September 1983, Research communications in chemical pathology and pharmacology,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
May 1991, Xenobiotica; the fate of foreign compounds in biological systems,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
August 1992, American journal of veterinary research,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
January 1981, European journal of clinical pharmacology,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
August 1982, Clinical pharmacology and therapeutics,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
September 1984, Xenobiotica; the fate of foreign compounds in biological systems,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
April 1991, Biochemical pharmacology,
M Danhof, and R M Verbeek, and C J van Boxtel, and J K Boeijinga, and D D Breimer
November 1989, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!